Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00618709 · ClinicalTrials.gov registry record · Phase 1
Dose-Escalation Safety and Pharmacokinetic Study of ATX-101
A Phase 1 study, sponsored by Kythera Biopharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00618709: Completed Phase 1 study, sponsored by Kythera Biopharmaceuticals.
NCT00618709 is a Phase 1 study that has completed, run by Kythera Biopharmaceuticals. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00618709, a Phase 1 study, has completed, sponsored by Kythera Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this research is to evaluate the safety and pharmacokinetic profile of single doses of ATX-101
Interventions
- DRUG ATX-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-01 |
| Phase | Phase 1 |
What the finished NCT00618709 record still lists
NCT00618709 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 1 intervention - of which ATX-101 is the first listed.
NCT00618709 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00618709 about?
NCT00618709 is a clinical study titled "Dose-Escalation Safety and Pharmacokinetic Study of ATX-101". The purpose of this research is to evaluate the safety and pharmacokinetic profile of single doses of ATX-101
What is the current status of trial NCT00618709?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2008-01. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00618709?
The interventions under investigation include: ATX-101 (DRUG).
Who is sponsoring clinical trial NCT00618709?
This trial is sponsored by Kythera Biopharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00618709's enrollment target sits among peer trials
24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia